Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Short term Debt (2019 - 2022)

Theravance Biopharma (TBPH) has disclosed Short term Debt for 4 consecutive years, with $9.0 million as the latest value for Q1 2022.

  • Quarterly Short term Debt fell 22.7% to $9.0 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Mar 2022, down 22.7% year-over-year, with the annual reading at $16.9 million for FY2021, 12.38% down from the prior year.
  • Short term Debt for Q1 2022 was $9.0 million at Theravance Biopharma, down from $16.9 million in the prior quarter.
  • The five-year high for Short term Debt was $19.3 million in Q4 2020, with the low at $6.9 million in Q2 2021.
  • Average Short term Debt over 4 years is $11.6 million, with a median of $10.8 million recorded in 2019.
  • The sharpest move saw Short term Debt soared 96.26% in 2020, then fell 22.7% in 2022.
  • Over 4 years, Short term Debt stood at $9.9 million in 2019, then skyrocketed by 96.26% to $19.3 million in 2020, then fell by 12.38% to $16.9 million in 2021, then plummeted by 46.8% to $9.0 million in 2022.
  • According to Business Quant data, Short term Debt over the past three periods came in at $9.0 million, $16.9 million, and $12.5 million for Q1 2022, Q4 2021, and Q3 2021 respectively.